Drug details

Akeega (niraparib and abiraterone acetate tablets)

type of Antiandrogens, Antineoplastics PARP Inhibitors

Akeega (niraparib and abiraterone acetate) is a combination a poly (ADP-ribose) polymerase (PARP) inhibitor and a CYP17 inhibitor indicated for use with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC).

The drug is often used to treat Prostate cancer .

This drug may have the following side effects:

• nausea,
• vomiting,
• fever,
• shortness of breath,
• weight loss,
• dizziness,
• constipation,
• musculoskeletal pain,
• headache,
• fatigue,
• cough,
• bleeding,
• insomnia,
• abdominal pain,
• urinary tract infection (UTI),
• decreased platelets,
• decreased hemoglobin,
• increased creatinine,
• high blood pressure (hypertension),
• decreased appetite,
• decreased white blood cells,
• fluid retention (edema),
• increased alkaline phosphatase,
• increased AST,
• COVID-19,
• irregular heartbeats (arrhythmia),
• falls,
• increased or decreased potassium,
• increased ALT, and
• increased bilirubin.

The following drugs are related to Akeega, either as a replacement or used together:

• Erleada (apalutamide tablets)
• Casodex (bicalutamide)
• Jevtana (cabazitaxel injection)
• Eligard (leuprolide acetate)
• Pluvicto (lutetium lu 177 vipivotide tetraxetan)
• Orgovyx (relugolix tablets)
• Provenge (sipuleucel-t suspension for intravenous infusion)
• Xofigo (radium ra 223 dichloride)
• Talzenna (talazoparib capsules)